However, we did detect decreases in proangiogenic factors such as MCSF-1 and MMP-9 in the shEGFR-MDA-231 cells, as well as a panel of breast cancer cell lines treated with an EGFR tyrosine kinase inhibitor or PAR-34. Here, MMP9 is linked to breast carcinoma.